London, 19 - 20 March 2024
Schedule
Create your personal agenda –check the favourite icon
Mar 198:59
Conference pass
Chair: Miguel Forte, President Elect, ISCT; Entrepreneur in Residence, AdBio Partners
Keynotes
Miguel Forte, President Elect, ISCT; Entrepreneur in Residence, Adbio partners
Keynote
Mar 199:05
Conference pass
Opening remarks
Keynotes
Miguel Forte, President Elect, ISCT; Entrepreneur in Residence, Adbio partners
Keynote
Mar 199:30
Conference pass
Keynote panel: Looking ahead: Key considerations for ensuring the commercial sustainability of ATMPs
Keynotes
- Tackling the key barriers and opportunities to commercialisation
- Looking ahead, commercialisation today and preparing for the future
Miguel Forte, President Elect, ISCT; Entrepreneur in Residence, Adbio partners
David Fontana, Chief Operating Officer, Umoja Biopharma
Keynote
Mar 1911:00
Conference pass
Roundtables
Keynotes
Roundtable 1: In vivo generation of therapeutic cells – CAR-T and beyond
David Peritt, Chief Scientific Officer, Lupagen
Roundtable 4:Tackling the challenges of getting to commercial level
Imen Mestiri, Business Development Manager, GENETHON
Roundtable 5: Streamlining your vector processing pipeline
Paul S Carter, Director, Head Vector Processing, Quell Therapeutics
Roundtable 6: Interactions with Regulatory Authorities for SMEs and Academia
Margareth Jorvid, Head of Regulatory Affairs, Ilya Pharma
Roundtable 8: Patient Advocacy Groups Accelerating Research – How to engage and best practice sharing
Margareth Jorvid, Head of Regulatory Affairs, Ilya Pharma
Mar 1912:59
Conference pass
Chair: Alexander Natz, Secretary General, European Confederation of Pharmaceutical Entrepreneurs (EUCOPE)
Evidence, Pricing & Access
Alexander Natz, Director General, EUCOPE - European Confederation of Pharmaceutical Entrepreneurs
Track 1
Mar 1912:59
Conference pass
Chair: Stefanos Theoharis, Consultant, Independent
Gene Modified Cell Therapy
Stefanos Theoharis, Chief Business Officer, Independent
Track 2
Mar 1912:59
Conference pass
Chair: Francesco Dazzi, Medical Director of Cell Therapy, AstraZeneca
Cell Therapy
Francesco Dazzi, Professor of Regenerative Medicine, King’s College London Executive & Medical Lead, Cell Therapy, AstraZeneca
Track 3
Mar 1912:59
Conference pass
Chair: Eric Michael David, CEO, BridgeBio Gene Therapy
Gene Therapy
Eric Michael David, Chief Executive Officer, BridgeBio Gene Therapy
Track 4
Mar 1912:59
Conference pass
Chair: Holger Laux, Director, Viral Vector Process Development, CSL Behring
Viral Vector Manufacturing
Holger Laux, Director of Viral Vector Process Development, CSL Behring
Track 6
Mar 1912:59
Conference pass
Chair: Lior Raviv, CTO, Pluri
Supply Chain & Logistics
Lior Raviv, Vice President, Development & Operations, Pluri
Track 7
Mar 1912:59
Conference pass
Chair: Roy Baynes, EVP and CMO, Eikon Therapeutics
Immunotherapy
Roy Baynes, Senior Vice President Clinical Research, Merck Research Laboratories
Track 8
Mar 1912:59
Conference pass
Chair: David Morrow, Scientific Program Manager, EATRIS
Innovation Showcase
David Morrow, scientist, eatris
Track 9
Mar 1912:59
Conference pass
Chair: Owen Smith, Partner, 4BIO Capital
Start-up Showcase
Owen Smith, Partner, 4BIO Capital
Track 10
Mar 1913:00
Conference pass
How real-world evidence can inform decision-making for ATMPs: a Danish case study
Evidence, Pricing & Access
Track 1
Mar 1913:00
Conference pass
miCAR Multiplex Cell Engineering: The new standard
Gene Modified Cell Therapy
Sven Kili, Principal, Sven Kili Consulting
Track 2
Mar 1913:00
Conference pass
Cell therapy for cardiovascular disease
Cell Therapy
Gabor Foldes, senior medical director, AstraZeneca
Track 3
Mar 1913:00
Conference pass
How NHS and Industry can work side by side to facilitate GMP manufacture early stage trials
Cell Therapy Manufacturing
Owen Bain, Director, Centre for Cell Gene Tissue Therapeutics, Royal Free NHS Trust
Track 5
Mar 1913:00
Conference pass
Immune secretomes targeting age-acquired immune decline
Immunotherapy
Hans Keirstead, Chairman, Immunis Inc.
Track 8
Mar 1913:00
Conference pass
Supporting the development of a European Research and Development Ecosystem for Rare Diseases. The Why and the How
Innovation Showcase
David Morrow, scientist, eatris
Track 9
Mar 1913:00
Conference pass
Investor panel: How to attract investment into cell and gene therapy: Hear how different investors decide on who and what they invest in, and why
Start-up Showcase
Owen Smith, Partner, 4BIO Capital
Edward Hodgkin, Chief Executive Officer, Resolution Therapeutics
Sven Kili, Principal, Sven Kili Consulting
Kerstin Papenfuss, Associate Director Pharma, Deep Science Ventures
Track 10
Mar 1913:20
Conference pass
Panel: Utilising real-world evidence for the advancement of cell and gene therapies
Evidence, Pricing & Access
Nneka Onwudiwe, Former PRO/PE Regulatory Review Officer, Food and Drug Administration (FDA)
Entela Xoxi, Senior Researcher, Università Cattolica Sacro Cuore Roma
Karen Facey, Facilitator, RWE4Decisions
Michael von Forstner, Head of Safety Science, Global Pharmacovigilance and Patient Safety, Sobi (Swedish Orphan Biovitrum)
David Foldes, Senior Clinical Research Fellow, Imperial College London
Track 1
Mar 1913:20
Conference pass
Targeting of HLA-G positive tumors with cytotoxic immune cells engineered with a Chimeric ILT-Receptor
Gene Modified Cell Therapy
Track 2
Mar 1913:20
Conference pass
Cell therapy for Parkinson’s disease
Cell Therapy
Track 3
Mar 1913:20
Conference pass
First experiences of launching a ATMP in Europe: a company’s view
Gene Therapy
Track 4
Mar 1913:20
Conference pass
Presentation from ScaleReady
Cell Therapy Manufacturing
Track 5
Mar 1913:20
Conference pass
T cell co-engineering strategies for safely improving tumour control
Viral Vector Manufacturing
Melita Irving, Group Leader T-Cell Engineering, University of Lausanne
Track 6
Mar 1913:20
Conference pass
Targeting cancer with a new comprehensive stem cell-based immunotherapy
Immunotherapy
Stephen Sullivan, Chief Operating Officer, IPSirius
Track 8
Mar 1913:20
Conference pass
Targeting cancer with a new comprehensive stem cell-based immunotherapy
Immunotherapy
Stephen Sullivan, Chief Operating Officer, IPSirius
Track 8
Mar 1913:20
Conference pass
Engineering neurogenesis via lineage reprogramming
Innovation Showcase
Benedikt Berninger, Professor of Developmental Neurobiology, King's College London
Track 9
Mar 1913:40
Conference pass
Clinical updates: Leveraging Moderna’s mRNA platform to advance medicines for rare disease patients
Gene Therapy
Paolo Martini, CSO Rare Diseases, Hematology and Rare Alliances,, Moderna Therapeutics
Track 4
Mar 1914:00
Conference pass
Transition of a hospital set ATMP into an outpatient setting and its reimbursement implications for a novel Autologous Chondrocyte Implantation
Evidence, Pricing & Access
Andre Roeder, Head, Global Market Access, TETEC AG
Track 1
Mar 1914:00
Conference pass
Autologous cells for muscle regeneration: a translational clinical trial perspective
Cell Therapy
Deana Mohr, Chief Executive Officer, MUVON Therapeutics
Track 3
Mar 1914:00
Conference pass
The first renal gene therapies - from academia to biotech to clinical trials
Gene Therapy
Moin Saleem, Founder and Chief Scientific Advisor, Purespring Therapeutics
Track 4
Mar 1914:00
Conference pass
Development of a perfusion process for continuous lentivirus production using stable suspension producer cell lines
Viral Vector Manufacturing
Holger Laux, Director of Viral Vector Process Development, CSL Behring
Track 6
Mar 1914:00
Conference pass
Panel: How can we better organise clinical trial supply chains to benefit future commercial operations?
Supply Chain & Logistics
Tamas Masztis, Senior Director, International Cell and Gene Theraphy Supply Chain, Vertex Pharmaceuticals
Track 7
Mar 1914:00
Conference pass
Clinical update, cancer vaccines
Immunotherapy
Eric Halioua, President & Chief Executive Officer, PDC*line pharma SA
Track 8
Mar 1914:00
Conference pass
Panel Discussion: Diversity, equity and inclusion in Advanced Therapies
Innovation Showcase
Laura Koivusalo, Chief Executive Officer & Founder, StemSight
Track 9
Mar 1914:00
Conference pass
Title TBC
Start-up Showcase
Stefan Lukianov, Chief Executive Officer, Salve Therapeutics
Track 10
Mar 1914:20
Conference pass
Pipeline update: Genetically-Engineered TIL Therapies
Gene Modified Cell Therapy
John Bridgeman, Director of Cell Therapy Research, Instil Bio
Track 2
Mar 1914:20
Conference pass
Evolving strategies for cell and gene therapy
Cell Therapy
Mayur Goyal, Head, Commercial & Pipeline Strategy, Cell & Gene Therapies, Novartis
Track 3
Mar 1914:20
Conference pass
A manufacturing platform for mesenchymal stem cell expansion
Cell Therapy Manufacturing
Josef Christensen, Chief Business Development Officer, StemMedical
Track 5
Mar 1914:20
Conference pass
CAR T-cell immunotherapy of solid tumours – moving through the generations
Immunotherapy
John Maher, CSO, Leucid Bio
Track 8
Mar 1914:20
Conference pass
Title TBC
Start-up Showcase
Mari Carmen Alvarez, Project Director, Tetraneuron
Track 10
Mar 1914:40
Conference pass
Panel: What do the new EUHTA Regulations mean for ATMPs in Europe?
Evidence, Pricing & Access
Alexander Natz, Director General, EUCOPE - European Confederation of Pharmaceutical Entrepreneurs
Dilip Patel, VP Market Access, Autolus
Marcus Droege, Vice President, Global Value & Market Access, Passage Bio
Thomas Mueller, Head Of Directorate General 1 - Drugs, Medical Devices, Biotechnology, Federal Ministry of Health Germany
Track 1
Mar 1914:40
Conference pass
Catalyzing success - the Medace model for clinical manufacturing
Start-up Showcase
A hybrid approach combining the best of outsourcing and DIY excellence
Track 10
Mar 1915:00
Conference pass
Development of Selected Tumor Infiltrating Lymphocyte Therapies for Solid Tumors
Gene Modified Cell Therapy
Stewart Abbot, CSO, Turnstone Biologics
Track 2
Mar 1915:00
Conference pass
Clinical update
Cell Therapy
Chris Williams, SVP, Corporate Development, Autolus Therapeutics
Track 3
Mar 1915:00
Conference pass
Controlling Manufacturing Processes in Pre-commercial and Commercial Autologous Cell & Gene Therapy Products
Cell Therapy Manufacturing
Elena Costariol, MSAT scientist, Orchard Therapeutics
Track 5
Mar 1915:00
Conference pass
Title TBC
Supply Chain & Logistics
Chris Baldwin, Senior Director of Cell and Gene Therapy Supply Chain, GlaxoSmithKline Plc
Track 7
Mar 1915:00
Conference pass
Next Generation Immunotherapies for Cancer and Autoimmune Diseases
Immunotherapy
Thomas Prod'homme, Vice President, Translational Research, Myeloid Therapeutics
Track 8
Mar 1915:00
Conference pass
Delivering the promise of nucleic acid therapeutics
Innovation Showcase
Nick Lench, Executive Director, Nucleic Acid Therapy Accelerator (NATA)
Track 9
Mar 1915:00
Conference pass
Clinical development of activated Treg - cell therapeutic approach for immunologically mediated diseases
Start-up Showcase
Prof. Dr. Andrea Tüttenberg, Chief Executive Officer, ActiTrexx GmbH
Track 10
Mar 1915:50
Conference pass
Panel: Finding the right framework for reimbursement and market access
Evidence, Pricing & Access
Alexander Natz, Director General, EUCOPE - European Confederation of Pharmaceutical Entrepreneurs
Dilip Patel, VP Market Access, Autolus
Track 1
Mar 1915:50
Conference pass
Engineering the next-generation of programmable cell therapies
Gene Modified Cell Therapy
David Venables, Chief Executive Officer, Laverock Therapeutics
Track 2
Mar 1915:50
Conference pass
Genetic changes in human pluripotent stem cells: Implications for safety and efficacy of cell therapies
Cell Therapy
Ivana Barbaric, Professor of Stem Cell Biology, The University of Sheffield
Track 3
Mar 1915:50
Conference pass
Novel Gene therapy treatment for Severe Chronic Pain
Gene Therapy
Karin Agerman, CSO, CombiGene
Track 4
Mar 1915:50
Conference pass
Addressing challenges in viral vector manufacturing to support academics taking novel gene therapies to the clinic
Viral Vector Manufacturing
Sophie Mountcastle, Network Manager - Innovation Hubs for Gene Therapies, Medical Research Council
Track 6
Mar 1916:10
Conference pass
Streamlining Clinical Success: Bioprocessing for Multinational Cell Therapy Trials
Cell Therapy Manufacturing
Ben Weil, Director of Manufacturing, INmune Bio
Track 5
Mar 1916:10
Conference pass
Presentation from BiologIC Technologies
Innovation Showcase
Jo Miller, Director, Cell Therapy Sciences
Track 9
Mar 1916:30
Conference pass
Autologous vs, allogeneic
Gene Modified Cell Therapy
Mayur Goyal, Head, Commercial & Pipeline Strategy, Cell & Gene Therapies, Novartis
Laura Koivusalo, Chief Executive Officer & Founder, StemSight
Track 2
Mar 1916:30
Conference pass
Panel: Using pre-clinical models efficiently to avoid failure of clinical trials
Cell Therapy
Moin Saleem, Founder and Chief Scientific Advisor, Purespring Therapeutics
Track 3
Mar 1916:30
Conference pass
Panel: Gene therapy for the brain
Gene Therapy
Eric Michael David, Chief Executive Officer, BridgeBio Gene Therapy
Karin Agerman, CSO, CombiGene
Pedro Gonzalez-Alegre, Head of Gene Therapy Research, Spark Therapeutics
Rahul Kaushik, Group leader, Evox Therapeutics
Track 4
Mar 1916:30
Conference pass
Panel Discussion: Points to consider when building supply chain operations from scratch
Supply Chain & Logistics
Tamas Masztis, Senior Director, International Cell and Gene Theraphy Supply Chain, Vertex Pharmaceuticals
Shree Patel, EVP Patient Supply Operations, Achilles Therapeutics Limited
Track 7
Mar 1916:50
Conference pass
The last 5 years in ATMPs: What went wrong with Zynteglo and what are the lessons learned from Libmeldy?
Evidence, Pricing & Access
Alexander Natz, Director General, EUCOPE - European Confederation of Pharmaceutical Entrepreneurs
Track 1
Mar 1916:50
Conference pass
Manufacturing strategies for academic and commercial studies
Cell Therapy Manufacturing
Barry Flutter, Head Of Product Manufacturing, GOSH
Track 5
Mar 1916:50
Conference pass
Staying One Step Ahead of Workforce Trends Impacting Your Business
Innovation Showcase
Angela Justice, Chief People Officer, TCR² Therapeutics
Track 9
Mar 1917:10
Conference pass
AI applications for cell therapy
Cell Therapy
Simon Bornschein, Founder & Chief Executive Officer, coding.bio
Track 3
Mar 1917:10
Conference pass
Quantitative Synthetic Biology to Advance Viral Vector Production
Viral Vector Manufacturing
Kevin Smith, Head of Technology Development: Synthetic Biology, Cell Line Development, Process Development, Asimov
Track 6
Mar 1917:30
Conference pass
The evolution of the Implementation of Managed Entry Agreements in Italy: focus on the ATMPs
Evidence, Pricing & Access
Entela Xoxi, Senior Researcher, Università Cattolica Sacro Cuore Roma
Track 1
Mar 1917:30
Conference pass
Clinical development of iPSC-derived mesenchymal stem cells
Cell Therapy
Track 3
Mar 1917:30
Conference pass
Gene therapy programme update
Gene Therapy
Graciana Diez Roux, Chief Scientific Officer, Tigem
Track 4
Create your personal agenda –check the favourite icon
Mar 208:54
Conference pass
Chair: Paolo Morgese, Head of Public Affairs, Europe ARM
Keynotes
Paolo Morgese, Head of Public Affairs, Europe, Alliance for Regenerative Medicine
Keynote
Mar 208:55
Conference pass
Introduction from chair
Keynotes
Paolo Morgese, Head of Public Affairs, Europe, Alliance for Regenerative Medicine
Keynote
Mar 209:00
Conference pass
Keynote Panel: Review of current regulatory landscape
Keynotes
Paolo Morgese, Head of Public Affairs, Europe, Alliance for Regenerative Medicine
Janet Glassford, Senior Quality Assessor, Medicines & Healthcare products Regulatory Agency
Peter Marks, Director, Center For Biologics Evaluation And Research (CBER), U.S. Food and Drug Administration
Keynote
Mar 209:30
Conference pass
Tackling the challenges of global adoption of cell and gene therapies
Keynotes
Addressing the economic challenges of global adoption & how we can ensure therapies reach the patients most in need
Paolo Morgese, Head of Public Affairs, Europe, Alliance for Regenerative Medicine
Marijn Verhoef, Director of Research and Operations, Access to Medicine Foundation
Daniel Gibson, Director, Cell and Gene Therapy Services, Anthony Nolan
Michela Zuccolo, Gene Therapy and Rare Strategy, F. Hoffmann-La Roche
Gunter Harms, Senior Director, Patient Access, Germany, Austria, Switzerland, novartis gene therapies
Keynote
Mar 2010:59
Conference pass
Chair: Dominic O’Regan, Business Development Consultant, Investor, New Mosaic
Start-up Showcase
Dominic O'Regan, Business Development Consultant & Investor, New Mosaic
Track 10
Mar 2010:59
Conference pass
Snehal Naik Head of Regulatory Policy; Strategy Leader (Ocular), Spark Therapeutics
Regulation
Snehal Naik, Head of Regulatory Policy; Strategy Leader (Ocular), Spark Therapeutics
Track 1
Mar 2010:59
Conference pass
Chair: Jaap Boelens, Chief, Transplantation and Cellular Therapies, MSK Kids, Memorial Sloan Kettering Cancer Center
Clinical Development
Jaap Boelens, Chief, Stem Cell Transplantation And Cellular Therapies Pediatrics, Memorial Sloan-Kettering Cancer Center
Track 7
Mar 2010:59
Conference pass
Chair: Devyn Smith, CEO, Arbor Biotechnology
Gene Editing
Devyn Smith, Chief Executive Officer, Arbor Biotechnologies
Track 8
Mar 2011:00
Conference pass
Targeted Delivery of Therapeutic Payloads Using Stem Cell- Derived Exosomes
Cell Therapy
Randolph Corteling, CSO, ReNeuron
Track 3
Mar 2011:00
Conference pass
Advancing Known and Novel Capsids to Deliver Gene Therapies to the Heart
Gene Therapy
Kathy Ivey, Vice President of Gene Therapy Research, Tenaya Therapeutics
Track 4
Mar 2011:00
Conference pass
AI driven decentralised production
Cell Therapy Manufacturing
Ioannis Papantoniou, Assoc. Professor of Tissue Engineering and Biomanufacturing, Prometheus division of Skeletal Tissue Engineering, KU Leuven
Track 5
Mar 2011:00
Conference pass
Advancing drug discovery by measuring protein dynamics through single molecule tracking (SMT)
Innovation Showcase
Roy Baynes, Senior Vice President Clinical Research, Merck Research Laboratories
Track 9
Mar 2011:00
Conference pass
Panel: Ask the investors
Start-up Showcase
Gregory Fiore, Chief Executive Officer, Exacis Biotherapeutics
Lucia Faccio, Partner Sofinnova Telethon Fund, Sofinnova Partners
Dominic O'Regan, Business Development Consultant & Investor, New Mosaic
David Greenwald, Vice President Of Business Development, Deerfield Management
Track 10
Mar 2011:00
Conference pass
An update on the European Association of Hospital Pharmacy (EAHP) gene therapy medicinal product guidelines
Regulation
Nicola Stoner, Consultant Pharmacist, Oxford University Hospitals N.H.S. Trust
Track 1
Mar 2011:00
Conference pass
How do we involve the patients most in need of treatment?
Clinical Development
Paul Gissen, Professor of Metabolic Medicine, Head of Gene and Stem Cell Therapy, UCL Great Ormond Street Institute of Child Health
Track 7
Mar 2011:00
Conference pass
Next gen gene editing
Gene Editing
Devyn Smith, Chief Executive Officer, Arbor Biotechnologies
Track 8
Mar 2011:20
Conference pass
B cell engineering as a novel platform for the treatment of evolving diseases
Cell Therapy
Alessio Nahmad, Co-Founder, Tabby Therapeutics
Track 3
Mar 2011:20
Conference pass
Genethon: Developing gene therapy for rare diseases
Gene Therapy
Angela Columbano, Head Business Development Partnership, GENETHON
Track 4
Mar 2011:20
Conference pass
Fully automated cell expansion for the production of three-dimensional functional implants
Cell Therapy Manufacturing
Track 5
Mar 2011:20
Conference pass
CMC Regulatory Challenges for ATMPs
Regulation
Natalie Ward, Director, Regulatory Affairs CMC, Adaptimmune
Track 1
Mar 2011:20
Conference pass
Accelerating Research - From Basic Science to Clinical Trials
Clinical Development
Katherine Forsey, Chief Research Officer (based in the UK), Charcot Marie Tooth Association
Track 7
Mar 2011:20
Conference pass
Unmasking Cas9: Exploring the Immunogenicity of CRISPR-Cas9 Gene Editing System
Gene Editing
Roberto Nitsch, Director, AstraZeneca
Track 8
Mar 2011:40
Conference pass
Global Renal Autologous Cell Therapy (REACT) Treating Diabetic CKD: Phase 3 Challenges in Operations and the Supply Chain
Cell Therapy
Joseph Stavas, Senior Vice President of Clinical Development, ProKidney
Track 3
Mar 2012:00
Conference pass
In-vivo therapeutics
Gene Modified Cell Therapy
David Peritt, Chief Scientific Officer, Lupagen
Track 2
Mar 2012:00
Conference pass
Initial clinical results of iPSC-based remuscularization therapy
Cell Therapy
Kikuo Yasui, Chief Operating Officer, Director of the Board, Heartseed Inc.
Track 3
Mar 2012:00
Conference pass
Title TBC
Cell Therapy Manufacturing
Lior Raviv, Vice President, Development & Operations, Pluri
Track 5
Mar 2012:00
Conference pass
Systematic Serendipity: a methodology for developing new treatments for rare diseases
Innovation Showcase
Ron Jortner, Founder & Chief Executive Officer, Aspire Biosciences
Track 9
Mar 2012:00
Conference pass
Panel: Regulatory session for academic and early-stage companies
Regulation
Victoria English, Co-Founder And Editor, Evernow Publications
Margareth Jorvid, Head of Regulatory Affairs, Ilya Pharma
Track 1
Mar 2012:00
Conference pass
Fillings gaps, tackling challenges between clinical development and real-world evidence. Case experience in kidney rare and orphan disease area
Clinical Development
Domenico Merante, Global Clinical Development Therapeutic Area Clinical Lead Nephrology & Orphan/Rare Diseases, CSL Vifor
Track 7
Mar 2012:00
Conference pass
Panel Discussion: Safety in gene editing
Gene Editing
Devyn Smith, Chief Executive Officer, Arbor Biotechnologies
Track 8
Mar 2012:20
Conference pass
Clinical trial update: Cell therapy for type 1 diabetes
Cell Therapy
Lindsay Davies, CSO, NextCell Pharma
Track 3
Mar 2012:20
Conference pass
Gene therapy strategies and considerations for the vector design
Gene Therapy
Rahul Kaushik, Group leader, Evox Therapeutics
Track 4
Mar 2012:20
Conference pass
Manufacturing for allogeneic cell therapies
Cell Therapy Manufacturing
Ricardo Baptista, Chief Technology Officer, Alder Therapeutics
Track 5
Mar 2012:20
Conference pass
The Reality of a Revolution: Hopes and Disappointments in Advanced Therapies
Clinical Development
David Foldes, Senior Clinical Research Fellow, Imperial College London
Track 7
Mar 2012:40
Conference pass
Challenges and opportunities for the clinical development of gene therapies in rare diseases
Gene Therapy
Oscar Segurado, Chief Medical Officer, Asc Therapeutics
Track 4
Mar 2012:40
Conference pass
Considerations for biosafety testing of cell and gene therapies
Cell Therapy Manufacturing
Richard Adair, Virology Manager, SGS Vitrology Limited
Track 5
Mar 2013:59
Conference pass
Chair: Holger Laux, Director, Viral Vector Process Development, CSL Behring
Viral Vector Manufacturing
Holger Laux, Director of Viral Vector Process Development, CSL Behring
Track 6
Mar 2013:59
Conference pass
Chair: Dominic O’Regan, Business Development Consultant, Investor, New Mosaic
Start-up Showcase
Dominic O'Regan, Business Development Consultant & Investor, New Mosaic
Track 10
Mar 2013:59
Conference pass
Chair: Jaap Boelens, Chief, Transplantation and Cellular Therapies, MSK Kids, Memorial Sloan Kettering Cancer Center
Clinical Development
Jaap Boelens, Chief, Stem Cell Transplantation And Cellular Therapies Pediatrics, Memorial Sloan-Kettering Cancer Center
Track 7
Mar 2013:59
Conference pass
Chair: Devyn Smith, CEO, Arbor Biotechnology
Gene Editing
Devyn Smith, Chief Executive Officer, Arbor Biotechnologies
Track 8
Mar 2013:59
Conference pass
Chair: Joanne Kurtzberg, Professor Paediatrics & Pathology, Duke University School of Medicine
Cord Blood & Tissue
Joanne Kurtzberg, Professor Of Pediatrics And Pathology; Director, Marcus Center For Cellular Cures,, Duke University Medical Center
Track 2
Mar 2014:00
Conference pass
Harnessing the Potential of the Incubator of Life: allogeneic amnion epithelial cells to Support Regeneration or Correction in Congenital and Chronic Disorders, without Immunosuppression
Cell Therapy
Roberto Gramignoli, Sr Researcher, Karolinska Institutet
Track 3
Mar 2014:00
Conference pass
Towards the optimal ‘Package’ therapy Jaap Boelens, Chief, Transplantation and Cellular Therapies
Clinical Development
Jaap Boelens, Chief, Stem Cell Transplantation And Cellular Therapies Pediatrics, Memorial Sloan-Kettering Cancer Center
Track 7
Mar 2014:20
Conference pass
Commercialising gene therapies
Gene Therapy
Mana Yen, Global Executive Director - Health systems, Novartis Gene Therapies
Track 4
Mar 2014:20
Conference pass
Panel Discussion: Strategies to increase patient involvement in the development of therapies
Clinical Development
Nicola Redfern, Director, NJ Redfern Ltd.
Samantha Barber, Chief Executive Officer, Gene People
Daniel Lewi, Co-founder & Chief Executive Officer, The Cure & Action for Tay-Sachs (CATS) Foundation
Paul Gissen, Professor of Metabolic Medicine, Head of Gene and Stem Cell Therapy, UCL Great Ormond Street Institute of Child Health
Track 7
Mar 2015:50
Conference pass
Developing optimal stem cell expansion and differentiation protocols for advanced cell
Cell Therapy
Marina Tarunina, Research Director, Plasticell
Track 3
Mar 2015:50
Conference pass
Gene Therapy Implementation in hospitals – challenges and tips for MA holders and Sponsors
Gene Therapy
Anne Black, QA Specialist Pharmacist, NHS Specialist Pharmacy Service
Track 4
Mar 2015:50
Conference pass
Real world evidence in the design and conduct of clinical trials
Clinical Development
Michael von Forstner, Head of Safety Science, Global Pharmacovigilance and Patient Safety, Sobi (Swedish Orphan Biovitrum)
Track 7
Mar 2016:10
Conference pass
Title TBC
Cell Therapy
Edward Hodgkin, Chief Executive Officer, Resolution Therapeutics
Track 3
Mar 2016:10
Conference pass
Gene Therapy for Rare Respiratory Diseases
Gene Therapy
Uta Griesenbach, Professor, Molecular Medicine, National Heart And Lung Institute; President, British Society For Gene And Cell Therapy;, Imperiai College London
Track 4
Mar 2016:50
Conference pass
Harnessing Baculoviruses as Gene Therapy Vectors
Viral Vector Manufacturing
Alexandra Harrison, PhD Student, University of Bristol
Track 6
last published: 07/Nov/23 09:35 GMT
Get Involved with the Advanced Therapies Congress
Created by
Terrapinn is proud to be a member of isla.
Working together to build sustainable events